A Single-center, Open-label, Randomized, Two-part, Two-treatment, Two-period Crossover Study to Investigate the Effect of Gemfibrozil or Rifampicin on the Pharmacokinetics of Selexipag and Its Metabolite ACT-333679 in Healthy Male Subjects.

Trial Profile

A Single-center, Open-label, Randomized, Two-part, Two-treatment, Two-period Crossover Study to Investigate the Effect of Gemfibrozil or Rifampicin on the Pharmacokinetics of Selexipag and Its Metabolite ACT-333679 in Healthy Male Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Selexipag (Primary) ; Gemfibrozil; Rifampicin
  • Indications Arteriosclerosis obliterans; Pulmonary arterial hypertension; Pulmonary hypertension; Raynaud's disease
  • Focus Pharmacokinetics
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 17 Jul 2017 Results published in the British Journal of Clinical Pharmacology
    • 27 Jun 2017 Results (n=20) from part II of the study assessing the effect of rifampicin on the pharmacokinetics of selexipag and ACT-333679, presented at the 13th Congress of the European Association for Clinical Pharmacology and Therapeutics
    • 27 Jun 2017 Results (n=20) from part I of the study assessing the effect of gemfibrozil on the pharmacokinetics of selexipag and ACT-333679, presented at the 13th Congress of the European Association for Clinical Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top